Salarius Pharmaceuticals, Inc. and VolitionRx Limited announced the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition's Nu.Q(R) technology to support further development of Salarius' clinical stage drug, seclidemstat. Seclidemstat, a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression, is currently in Phase 1/2 clinical studies for solid and hematologic cancers where LSD1 is implicated in disease progression. Nu.Q(R) has been developed as simple, easy-to-use, cost-effective blood tests to diagnose and monitor a range of life-altering diseases including cancer in humans and animals.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.489 USD | -0.59% | -0.18% | -24.77% |
25/03 | Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data | MT |
25/03 | Top Premarket Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.77% | 2.35M | |
+64.44% | 62.59B | |
-1.95% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.70% | 26.21B | |
-21.74% | 19.09B | |
+3.64% | 13.08B | |
+25.72% | 12.26B | |
+27.16% | 12.05B |
- Stock Market
- Equities
- SLRX Stock
- News Salarius Pharmaceuticals, Inc.
- Salarius Pharmaceuticals and VolitionRx Enters into Research and Development Collaboration Agreement